Your session is about to expire
← Back to Search
Cetuximab for Chordoma
Study Summary
This trial is testing a new drug to treat chordoma, a type of cancer. The target patient population is any chordoma patient 18 years of age with locally unresectable disease or metastatic disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2012 Phase 3 trial • 73 Patients • NCT01177956Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other experiments have been conducted utilizing Cetuximab?
"Presently, 122 Cetuximab studies are in progress with 30 trials at the third phase. Most of the clinical tests for this medication take place in Dresden, Arizona; however there are over 5500 other sites running such experiments."
To what extent has participation been observed in this experiment?
"Affirmative. According to clinicaltrials.gov, this medical trial is currently in search of participants and was initially published on May 27th 2022. A total of 15 people are needed at one location for the study which has most recently been updated on June 1st 2022."
Has the Food and Drug Administration authorized Cetuximab for public use yet?
"Cetuximab's safety has been supported to some extent, thus it was assigned a score of 2 on our scale. This is because this particular clinical trial is still in phase two and the efficacy hasn't been thoroughly demonstrated yet."
Are participants eligible to join this experiment currently?
"According to the records on clinicaltrials.gov, this trial is actively seeking volunteers; it was initially posted in late May and updated at the start of June."
What therapeutic benefits does Cetuximab typically provide?
"Cetuximab is widely prescribed as a pharmacotherapy for various medical conditions such as regionally advanced squamous cell carcinoma of the head and neck, metastatic hnscc, and general squamous cell carcinoma."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What state do they live in?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
How responsive is this trial?
Most responsive sites:
- M D Anderson Cancer Center: < 48 hours
Average response time
- < 2 Days
Typically responds via
Share this study with friends
Copy Link
Messenger